Status:
RECRUITING
Diet, Hepcidin, and Chemotherapy RDI
Lead Sponsor:
George Washington University
Conditions:
Breast Cancer Female
Ovarian Cancer
Eligibility:
FEMALE
21+ years
Brief Summary
This prospective, observational cohort study will evaluate the extent of associations between self-reported pro- or anti- inflammatory dietary intake patterns for one month before induction chemothera...
Detailed Description
This is a prospective, observational cohort of 100 women receiving chemotherapy for breast or gynecological cancer at GW Cancer Center from July 1, 2024 - approximately September 2025. At study baseli...
Eligibility Criteria
Inclusion
- Have been diagnosed with invasive breast cancer, OR
- Have been diagnosed with epithelial ovarian cancer, fallopian tube or primary peritoneal cancer, OR
- Have been diagnosed with endometrial cancer
- Are chemotherapy-naïve
- Are scheduled to receive neoadjuvant chemotherapy (or adjuvant chemotherapy following lumpectomy for breast cancer patients) or neoadjuvant/induction chemotherapy for gynecological cancer at GW Cancer Center
Exclusion
- Prior primary hematological condition that would cause abnormal blood counts (e.g. leukemia)
- Pregnant at the time of potential enrollment
- Receipt of erythropoietin-stimulating agents or blood transfusion in the 6 weeks prior to initial testing
- Women who are cognitively unable to provide a diet history for the month prior to assessment.
Key Trial Info
Start Date :
August 16 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06483997
Start Date
August 16 2024
End Date
July 1 2026
Last Update
October 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
George Washington University Cancer Center
Washington D.C., District of Columbia, United States, 20052